Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 2 of 18
Next
>>
>
26 to 50 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
BT-20	Everolimus	3	72	flat	flat	BT20 everolimus 0 3 72	8	2.422	Inf	0.475	0.456	0.0	0.475	0.01	0.602	0.0632	0.543	Inf	0.478	0.534	0.478	0.01	0.561	0.0844	0.534
BT-549	Alpelisib	1	72	flat	flat	BT549 alpelisib 0 1 72	8	1.822	Inf	0.747	0.0781	0.0	0.747	0.01	0.439	0.176	0.914	Inf	0.782	0.931	0.782	0.01	0.415	0.2	0.925
BT-20	XL147	2	72	flat	flat	BT20 pilaralisib 0 2 72	8	1.784	Inf	0.759	0.073	0.0	0.759	0.01	-0.0058	1.0	0.907	Inf	0.796	0.937	0.796	0.01	-0.00637	1.0	0.92
BT-549	XL147	3	72	flat	flat	BT549 pilaralisib 0 3 72	8	1.772	Inf	0.933	0.0351	0.0	0.933	0.01	-0.0699	1.0	0.962	Inf	0.941	0.969	0.941	0.01	-0.0712	1.0	0.967
BT-20	XL147	3	72	flat	flat	BT20 pilaralisib 0 3 72	8	2.647	Inf	0.755	0.102	0.0	0.755	0.01	0.0679	0.81	0.885	Inf	0.708	0.871	0.708	0.01	0.0505	0.856	0.857
BT-20	BX-912	1	72	flat	flat	BT20 BX-912 0 1 72	8	2.193	Inf	0.858	0.0928	0.0	0.858	0.01	0.25	0.422	0.903	Inf	0.851	0.901	0.851	0.01	0.243	0.433	0.897
BT-549	Alpelisib	3	72	flat	flat	BT549 alpelisib 0 3 72	8	1.743	Inf	0.817	0.068	0.0	0.817	0.01	-0.0192	1.0	0.915	Inf	0.846	0.942	0.846	0.01	-0.0162	1.0	0.928
BT-20	BX-912	2	72	flat	flat	BT20 BX-912 0 2 72	8	1.873	Inf	0.683	0.213	0.0	0.683	0.01	0.118	0.686	0.777	Inf	0.724	0.81	0.724	0.01	0.111	0.702	0.802
HCC38	Alpelisib	1	72	flat	flat	HCC38 alpelisib 0 1 72	8	1.738	Inf	0.757	0.0835	0.0	0.757	0.01	0.593	0.0674	0.909	Inf	0.798	0.929	0.798	0.01	0.579	0.0744	0.923
BT-20	BX-912	3	72	flat	flat	BT20 BX-912 0 3 72	8	2.619	Inf	0.904	0.0795	0.0	0.904	0.01	0.000173	0.999	0.918	Inf	0.879	0.9	0.879	0.01	0.00619	0.982	0.896
BT-20	KIN001-244	1	72	flat	flat	BT20 KIN001-244 0 1 72	8	2.125	Inf	0.911	0.0401	0.0	0.911	0.01	-0.00641	1.0	0.957	Inf	0.908	0.958	0.908	0.01	-0.00745	1.0	0.955
BT-20	TGX221	1	72	flat	flat	BT20 TGX-221 0 1 72	8	1.988	Inf	1.02	-0.00357	0.0	1.02	0.01	-0.00762	1.0	1.0	Inf	1.02	1.0	1.02	0.01	-0.00881	1.0	1.0
BT-20	KIN001-244	3	72	flat	flat	BT20 KIN001-244 0 3 72	8	2.608	Inf	0.841	0.062	0.0	0.841	0.01	0.489	0.133	0.935	Inf	0.805	0.922	0.805	0.01	0.475	0.145	0.919
BT-549	Sirolimus	3	72	flat	flat	BT549 rapamycin 0 3 72	8	1.703	Inf	0.455	0.482	0.0	0.455	0.01	0.376	0.243	0.518	Inf	0.582	0.626	0.582	0.01	0.436	0.179	0.625
BT-549	Everolimus	3	72	sigmoid	flat	BT549 everolimus 0 3 72	8	1.587	59.5	0.533	0.425	1e-05	0.395	0.1	0.702	0.0264	NA	Inf	0.656	0.685	0.656	0.01	0.48	0.141	0.685
BT-20	Everolimus	1	72	flat	flat	BT20 everolimus 0 1 72	8	2.002	Inf	0.546	0.403	0.0	0.546	0.01	-0.000401	1.0	0.595	Inf	0.597	0.638	0.597	0.01	-0.327	1.0	0.636
BT-20	Sirolimus	2	72	flat	flat	BT20 rapamycin 0 2 72	8	1.952	Inf	0.421	0.579	0.0	0.421	0.01	NA	NA	0.421	Inf	0.513	0.513	0.513	0.01	NA	NA	0.513
BT-20	CAL-101	1	72	flat	flat	BT20 idelalisib 0 1 72	8	2.112	Inf	0.869	0.0546	0.0	0.869	0.01	0.0807	0.777	0.938	Inf	0.867	0.943	0.867	0.01	0.0778	0.784	0.936
BT-20	XL147	1	72	flat	flat	BT20 pilaralisib 0 1 72	8	2.128	Inf	0.815	0.048	0.0	0.815	0.01	0.411	0.205	0.939	Inf	0.813	0.95	0.813	0.01	0.383	0.234	0.937
BT-20	CAL-101	2	72	flat	flat	BT20 idelalisib 0 2 72	8	1.768	Inf	0.818	0.0943	0.0	0.818	0.01	0.226	0.463	0.898	Inf	0.845	0.918	0.845	0.01	0.222	0.471	0.912
BT-20	Sirolimus	3	72	flat	flat	BT20 rapamycin 0 3 72	8	2.661	Inf	0.54	0.46	0.0	0.54	0.01	NA	NA	0.54	Inf	0.499	0.499	0.499	0.01	NA	NA	0.499
BT-20	CAL-101	3	72	flat	flat	BT20 idelalisib 0 3 72	8	2.589	Inf	0.916	0.0535	0.0	0.916	0.01	0.0547	0.845	0.944	Inf	0.894	0.932	0.894	0.01	0.0506	0.856	0.929
BT-20	Sirolimus	1	72	flat	flat	BT20 rapamycin 0 1 72	8	2.100	Inf	0.568	0.431	0.0	0.568	0.01	-9.89	1.0	0.568	Inf	0.6	0.601	0.6	0.01	-13.0	1.0	0.6
HCC70	Sirolimus	2	72	flat	flat	HCC70 rapamycin 0 2 72	8	1.762	Inf	0.685	0.257	0.0	0.685	0.01	0.531	0.103	0.741	Inf	0.739	0.785	0.739	0.01	0.524	0.108	0.783
HCC70	KIN001-244	3	72	flat	flat	HCC70 KIN001-244 0 3 72	8	2.472	Inf	0.916	0.0295	0.0	0.916	0.01	-0.0208	1.0	0.969	Inf	0.899	0.965	0.899	0.01	-0.00883	1.0	0.963

|<
<<
Previous
Page 2 of 18
Next
>>
>
26 to 50 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)